22 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 NEWS Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Biorasi, a global clinical research organization (CRO), today announced a strategic partnership to deliver fully integrated early phase clinical trial solutions. The partnership will combine Quotient Sciences’ expertise in early clinical development with Biorasi’s global patient recruitment capabilities to provide biotech and pharma Sponsors with a simplified, efficient pathway from Investigational New Drug (IND) to proof-of-concept (POC) with seamless transitions from healthy volunteers into patient groups within first-in-human (FIH) Phase I/IIa clinical trials. Sponsors will benefit from Quotient Sciences’ clinical pharmacology expertise, with facilities in Miami (US) and Nottingham (UK) comprising 230 beds and supported by a large database of trial participants. This is complemented by Biorasi’s global patient recruitment network, which spans a wide range of therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields. The partnership will provide sponsors with a single provider model for FIH to POC programs, with the option of a single contract and a unified protocol and regulatory submissions to reduce the outsourcing complexity and accelerate development timelines. Quotient Sciences is a recognized leader in early clinical development, with deep expertise in Phase I healthy volunteer studies and early patient proof-ofconcept (POC) trials. Quotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-concept
RkJQdWJsaXNoZXIy MjY2OTA4MA==